|
THIOUREA TASTING
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
|
|
|
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Methods:</b> Here, we investigated the impact of PTC-209, a small-molecule Bmi-1 inhibitor, on human cancer cell viability alone and in combination with anticancer drugs, namely, cisplatin, oxaliplatin, 5-fluorouracil, camptothecin, and Frondoside-A and its impact on cellular migration and colony growth <i>in vitro</i> and on tumor growth <i>in ovo</i>.
|
31695609 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
- Proposed noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTPs), formerly noninvasive encapsulated papillary carcinoma, follicular variant (PTC-FV), is an indolent tumor with follicular growth and frequent RAS mutations.
|
29582677 |
2018 |
|
Follicular neoplasm
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
- The morphologic similarity and RAS mutations in FAs, NIFTPs, and IE-PTC-FVs supports the genetic similarity of those follicular neoplasms in contrast to the unique presence of BRAF V600E mutations in PTC-EFGs.
|
29582677 |
2018 |
|
Thyroid Gland Noninvasive Follicular Neoplasm with Papillary-Like Nuclear Features
|
0.070 |
Biomarker
|
disease |
BEFREE |
- To detect histologic and molecular differences separating NIFTP from follicular adenomas (FAs) and invasive carcinomas, particularly papillary carcinomas with extensive follicular growth (PTC-EFGs) and invasive encapsulated PTC-FV (IE-PTC-FV).
|
29582677 |
2018 |
|
Follicular adenoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
- To detect histologic and molecular differences separating NIFTP from follicular adenomas (FAs) and invasive carcinomas, particularly papillary carcinomas with extensive follicular growth (PTC-EFGs) and invasive encapsulated PTC-FV (IE-PTC-FV).
|
29582677 |
2018 |
|
Carcinoma, Papillary
|
0.100 |
Biomarker
|
disease |
BEFREE |
- To detect histologic and molecular differences separating NIFTP from follicular adenomas (FAs) and invasive carcinomas, particularly papillary carcinomas with extensive follicular growth (PTC-EFGs) and invasive encapsulated PTC-FV (IE-PTC-FV).
|
29582677 |
2018 |
|
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
20 years of RET/PTC in thyroid cancer: clinico-pathological correlations.
|
17891236 |
2007 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
20 years of RET/PTC in thyroid cancer: clinico-pathological correlations.
|
17891236 |
2007 |
|
Carcinoma, Papillary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Papillary carcinomas show frequently a specific gene rearrangement which gives rise to the formation of several types of so-called RET/PTC chimeric genes.
|
10834397 |
2000 |
|
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Papillary thyroid carcinomas in humans are associated with the ret/PTC oncogene and, following loss of p53 function, may progress to anaplastic carcinomas.
|
10934169 |
2000 |
|
Neoplasms, Radiation-Induced
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
Radiation-induced tumors demonstrated a low prevalence (4%) of BRAF point mutations and high prevalence (58%) of RET/PTC rearrangements.
|
15145515 |
2004 |
|
Color blindness
|
0.020 |
Biomarker
|
disease |
BEFREE |
Colour-blindness and sensitivity to PTC in Hadza.
|
16431664 |
1975 |
|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thyroid carcinomas show a high prevalence of mutations in the oncogene BRAF which are inversely associated with RAS or RET/PTC oncogenic activation.
|
19878585 |
2009 |
|
familial non-medullary thyroid cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hereditary non-medullary thyroid cancer may occur as a minor component of familial cancer syndromes (e.g. familial adenomatous polyposis) or as a primary feature (familial non-medullary thyroid cancer [FNMTC]).Among FNMTC, PTC is the most common.
|
21049463 |
2011 |
|
Malignant neoplasm of thyroid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thyroid cancer (TC) is frequently associated with BRAF or RAS oncogenic mutations and RET/PTC rearrangements, with aberrant RAF-MEK-ERK and/or PI3K pathway activation.
|
26265449 |
2015 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thyroid cancer (TC) is frequently associated with BRAF or RAS oncogenic mutations and RET/PTC rearrangements, with aberrant RAF-MEK-ERK and/or PI3K pathway activation.
|
26265449 |
2015 |
|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thyroid cancer (TC) is frequently associated with BRAF or RAS oncogenic mutations and RET/PTC rearrangements, with aberrant RAF-MEK-ERK and/or PI3K pathway activation.
|
26265449 |
2015 |
|
Follicular Variant Thyroid Gland Papillary Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
FVPTC was significantly less likely to be classified sonographically as malignant (U5) (p = 0.006) or suspicious/malignant (U4/5) (p = 0.009) than conventional PTC.
|
28396943 |
2017 |
|
Locally Recurrent Malignant Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Locoregional recurrence is common in papillary thyroid cancer PTC and an optimal surgical treatment with respect to the multifocal nature of the disease stays controversial.
|
28550398 |
2018 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Papillary thyroid carcinoma (PTC) generally shows an excellent prognosis except in cases with aggressive backgrounds or clinicopathological features.
|
29349484 |
2018 |
|
Papillary Thyroid Microcarcinoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Papillary thyroid microcarcinoma (PTMC) accounts for nearly 50% of newly diagnosed PTC cases.
|
30196478 |
2018 |
|
Jaw Keratocyst
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PTC gene mutations and expression of SHH, PTC, SMO, and GLI-1 in odontogenic keratocysts.
|
15308259 |
2004 |
|
Coronary heart disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
TAS2R38 status was not an important determinant of CHD, related risk factors, or eating behavior in the British Women's Heart and Health Study sample.
|
15883422 |
2005 |
|
Cardiovascular Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
TAS2R38 haplotypes have been reported to influence food preferences (like cruciferous vegetables and fat foods) and cardiovascular disease risk factors.
|
21147709 |
2010 |